References
1. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019 Jan;7(1):e37-e46.
2. Platt MJ. Outcomes in preterm infants. Public Health. 2014 May;128(5):399-403.
3. UN Inter-agency Group for Child Mortality Estimation. Levels and trends in child mortality: report 2017, estimates developed by the UN Inter-agency Group for child mortality estimation. . New York: United Nations Children’s Fund; 2017.
4. Glass HC, Costarino AT, Stayer SA, Brett CM, Cladis F, Davis PJ. Outcomes for extremely premature infants. Anesth Analg. 2015 Jun;120(6):1337-51.
5. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000(2):CD000065.
6. Collaborators WAT. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials. 2019 Aug 16;20(1):507.
7. WHO. Recommendations on Interventions to Improve Preterm Birth Outcomes. Evidence and recommendations 2015 [cited 2018 12/2018]; Available from:https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/preterm-birth-guideline/en/
8. Managing complications in pregnancy and childbirth: a guide for midwives and doctors. 2nd ed. Geneva: World Health Organization; 2017.
9. Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2013 Aug 29(8):CD006764.
10. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017 Mar 21;3:CD004454.
11. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19(3):CD004454.
12. Crowther CA, Ashwood P, Andersen CC, Middleton PF, Tran T, Doyle LW, et al. Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial. Lancet Child Adolesc Health. 2019 Sep 12.
13. Mirzamoradi M, Hasani Nejhad F, Jamali R, Heidar Z, Bakhtiyari M. Evaluation of the effect of antenatal betamethasone on neonatal respiratory morbidities in late preterm deliveries (34-37 weeks). The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2019:1-8.
14. Ontela V, Dorairajan G, Bhat VB, Chinnakali P. Effect of Antenatal Steroids on Respiratory Morbidity of Late Preterm Newborns: A Randomized Controlled Trial. Journal of Tropical Pediatrics. 2018;64(6):531-8.
15. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2;162(11):777-84.
16. Binder LM, Iverson GL, Brooks BL. To Err is Human: “Abnormal” Neuropsychological Scores and Variability are Common in Healthy Adults. Archives of Clinical Neuropsychology. 2009;24(1):31-46.
17. Ciapponi A, Glujovsky D, Bardach A, García Martí S, Comande D. EROS: a new software for early stage of systematic reviews. HTAi 2011 Conference; 2011 June 27-29, 2011; Rio de Janeiro: Health Technology Assessment International (HTAi); 2011.
18. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation.
19. Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Chapter 11: Undertaking network meta-analyses. In: Higgins J, Thomas J, Chandler J, MS. C, Li T, Page M, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6 [updated September 2018]
Cochrane; 2018.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539-58.
21. Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol. 2002 Nov 13;2:13.
22. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012 Jun;3(2):98-110.
23. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013 Feb;42(1):332-45.
24. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010 Mar 30;29(7-8):932-44.
25. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012 Jun;41(3):818-27.
26. World Bank Country and Lending Groups. 2019 [cited 10.20/2019; Available from:https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
27. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.
28. Trinquart L, Attiche N, Bafeta A, Porcher R, Ravaud P. Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials. Ann Intern Med. 2016 May 17;164(10):666-73.
29. Veroniki AA, Straus SE, Rucker G, Tricco AC. Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis? J Clin Epidemiol. 2018 Aug;100:122-9.
30. Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol. 2016 Aug;76:193-9.
31. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Statistics and Computing. 2000 2000/10/01;10(4):325-37.
32. Review Manager (RevMan). [Computer program] Version 53 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
33. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
34. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018 Jan;93:36-44.
35. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol. 1981 Oct 1;141(3):276-87.
36. Amorim MMR, Santosa LC, Faúndes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. American Journal of Obstetrics and Gynecology. 1999 1999/05;180(5):1283-8.
37. Attawattanakul N, Tansupswatdikul P. Effects of antenatal dexamethasone on respiratory distress in late preterm infant: a randomized controlled trial. hai Journal of Obstetrics and Gynaecology. 2015;23(1):25‐33.
38. Balci O, Ozdemir S, Mahmoud AS, Acar A, Colakoglu MC. The Effect of Antenatal Steroids on Fetal Lung Maturation between the 34th and 36th Week of Pregnancy. Gynecologic and Obstetric Investigation. 2010;70(2):95-9.
39. Block MF, Kling OR, Crosby WM. Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstet Gynecol. 1977 Aug;50(2):186-90.
40. Cararach V, Botet F, Sentis J, Carmona F. A multicenter, prospective and randomized study in premature rupture of membranes (PROM). Maternal and perinatal complications. International journal of gynaecology and obstetrics. 1991;36 Suppl:267.
41. Carlan SJ, Parsons M, O’Brien WF, Krammer J. Pharmacologic pulmonary maturation in preterm premature rupture of membranes. American journal of obstetrics and gynecology. 1991;164:371.
42. Chen C-Y, Wang K-G, Chang T-Y, Chen C-P, Loo J-H. Effects of Antenatal Betamethasone and Dexamethasone in Preterm Neonates. Taiwanese Journal of Obstetrics and Gynecology. 2005 2005/09/01/;44(3):247-51.
43. Danesh A, Janghorbani M, Khalatbari S. Effects of antenatal corticosteroids on maternal serum indicators of infection in women at risk for preterm delivery: A randomized trial comparing betamethasone and dexamethasone. J Res Med Sci. 2012 Oct;17(10):911-7.
44. Doran TA, Swyer P, MacMurray B, Mahon W, Enhorning G, Bernstein A, et al. Results of a double-blind controlled study on the use of betamethasone in the prevention of respiratory distress syndrome. American Journal of Obstetrics and Gynecology. 1980 1980/02;136(3):313-20.
45. Egerman RS, Walker RA, Mercer BM, Doss JL, Sibai BM, Andersen RA. Comparison between oral and intramuscular dexamethasone in suppressing unconjugated estriol levels during the third trimester. Am J Obstet Gynecol. 1998 Nov;179(5):1234-6.
46. Elimian A, Garry D, Figueroa R, Spitzer A, Wiencek V, Quirk JG. Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):26-30.
47. Fekih M, Chaieb A, Sboui H, Denguezli W, Hidar S, Khairi H. [Value of prenatal corticotherapy in the prevention of hyaline membrane disease in premature infants. Randomized prospective study]. Tunis Med. 2002 May;80(5):260-5.
48. Gamsu HR, Mullinger BM, Donnai P, Dash CH. Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. British journal of obstetrics and gynaecology. 1989;96(4):401‐10.
49. Garite TJ, Rumney PJ, Briggs GG, Harding JA, Nageotte MP, Towers CV, et al. A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24 to 28 week’s gestation. American Journal of Obstetrics and Gynecology. 1992 1992/02;166(2):646-51.
50. Goodner DM. Antenatal steroids in the treatment of respiratory distress syndrome. 9th world congress of gynecology and obstetrics; 1979 october 26-31; tokyo, japan. 1979:362.
51. Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. New England journal of medicine. 2016;374(14):1311‐20.
52. Kari MA, Hallman M, Eronen M, Teramo K, Virtanen M, Koivisto M, et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics. 1994;93(5):730‐6.
53. Khandelwal M, Chang E, Hansen C, Hunter K, Milcarek B. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. American Journal of Obstetrics & Gynecology. 2012;206(3):201.e1-.e11.
54. Khazardoust S, Javadian P, Salmanian B, Zandevakil F, Abbasalizadeh F, Alimohamadi S, et al. A clinical randomized trial on endocervical inflammatory cytokines and betamethasone in prime-gravid pregnant women at risk of preterm labor. Iranian journal of immunology. 2012;9(3):199‐207.
55. Lewis D, Brody K, Edwards M, Brouillette R, Burlison S, London S. Preterm premature ruptured membranes: A randomized trial of steroids after treatment with antibiotics. Obstetrics & Gynecology. 1996 1996/11;88(5):801-5.
56. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50:515‐25.
57. Lopez L, Rojas L, Rodriguez V, Sanchez J. Use of corticoids in preterm pregnancy with premature rupture of membranes. Revista colombiana de obstetricia y ginecologia. 1989;40:147‐51.
58. Magee LA, Dawes GS, Moulden M, Redman CW. A randomised controlled comparison of betamethasone with dexamethasone: effects on the antenatal fetal heart rate. Br J Obstet Gynaecol. 1997 Nov;104(11):1233-8.
59. Mansouri M, Seyedolshohadaei F, Company F, Setare S, Mazhari S. Effect of antenatal Betamethasone on prevention of respiratory distress syndrome among neonates with gestational age of 35-36 weeks. Journal of Gorgan University of Medical Sciences. 2010;12(3):Pe18-Pe23, En109.
60. Morales WJ, Angel JL, O’Brien WF, Knuppel RA. Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstetrics and gynecology. 1989;73(5 Pt 1):721‐6.
61. Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol. 1997 Nov;104(11):1239-47.
62. Mushkat Y, Ascher-Landsberg J, Keidar R, Carmon E, Pauzner D, David MP. The effect of betamethasone versus dexamethasone on fetal biophysical parameters. Eur J Obstet Gynecol Reprod Biol. 2001 Jul;97(1):50-2.
63. Nelson LH, Meis PJ, Hatjis CG, Ernest JM, Dillard R, Schey HM. Premature rupture of membranes: a prospective, randomized evaluation of steroids, latent phase, and expectant management. Obstetrics and gynecology. 1985;66(1):55‐8.
64. Parsons MT, Sobel D, Cummiskey K, Constantine L, Roitman J. Steroid, antibiotic and tocolytic vs no steroid, antibiotic and tocolytic management in patients with preterm PROM at 25-32 weeks. Proceedings of 8th annual meeting of the society of perinatal obstetricians; 1988 feb 3-6; las vegas, nevada, USA. 1988:44.
65. Pattinson RC, Makin JD, Funk M, Delport SD, Macdonald AP, Norman K, et al. The use of dexamethasone in women with preterm premature rupture of membranes–a multicentre, double-blind, placebo-controlled, randomised trial. Dexiprom Study Group. South African medical journal. 1999;89(8):865‐70.
66. Porto AMF, Coutinho IC, Correia JB, Amorim MMR. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011 2011/04/12;342(apr12 1):d1696-d.
67. Qublan HS, Malkawi HY, Hiasat MS, Hindawi IM, Al-Taani MI, Abu-Khait SA, et al. The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clinical and experimental obstetrics & gynecology. 2001;28(3):183‐6.
68. Rotmensch S, Liberati M, Vishne TH, Celentano C, Ben-Rafael Z, Bellati U. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand. 1999 Jul;78(6):493-500.
69. Schutte MF, Treffers PE, Koppe JG, Breur W. The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after preterm labour. British journal of obstetrics and gynaecology. 1980;87(2):127‐31.
70. Senat MV, Minoui S, Multon O, Fernandez H, Frydman R, Ville Y. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol. 1998 Jul;105(7):749-55.
71. Shanks A, Gross G, Shim T, Allsworth J, Sadovsky Y, Bildirici I. Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. American Journal of Obstetrics and Gynecology. 2010 2010/07/01/;203(1):47.e1-.e5.
72. Silver RK, Vyskocil C, Solomon SL, Ragin A, Neerhof MG, Farrell EE. Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks’ gestation. Obstetrics and gynecology. 1996;87(5 Pt 1):683‐91.
73. Subtil D, Tiberghien P, Devos P, Therby D, Leclerc G, Vaast P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol. 2003 Feb;188(2):524-31.
74. Taeusch HW, Frigoletto F, Kitzmiller J, Avery ME, Hehre A, Fromm B, et al. Risk of respiratory distress syndrome after prenatal dexamethasone treatment. Pediatrics. 1979;63(1):64‐72.
75. Teramo K, Hallman M, Raivio KO. Maternal Glucocorticoid in Unplanned Premature Labor. Controlled Study on the Effects of Betamethasone Phosphate on the Phospholipids of the Gastric Aspirate and on the Adrenal Cortical Function of the Newborn Infant. Pediatric Research. 1980 1980/04;14(4):326-9.
76. Urban R, Lemancewicz A, Przepiesc J, Urban J, Kretowska M. Antenatal corticosteroid therapy: a comparative study of dexamethasone and betamethasone effects on fetal Doppler flow velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 2005 Jun 1;120(2):170-4.
77. Hong S, Lee SM, Kwak DW, Lee J, Kim SY, Oh JW, et al. Effects of antenatal corticosteroids in twin neonates with late preterm birth (ACTWIN [Antenatal Corticosteroids in TWIN late preterm neonates] trial): study protocol for a randomized controlled trial. BMC Pregnancy Childbirth. 2019 Apr 3;19(1):114.
78. 03547791 N. Effects of ACS in Twin With LPB: study Protocol for a RCT.Https://clinicaltrialsgov/show/nct03547791. 2018.
79. 03446937 N. Effect of Antenatal Corticosteroids on Neonatal Morbidity.Https://clinicaltrialsgov/show/nct03446937. 2018.
80. Cartwright R, Crowther C, Anderson P, Harding J, Doyle L, McKinlay C. Influence of fetal growth restriction on neurocognitive function after repeat antenatal betamethasone: secondary analysis of a randomised trial. Journal of paediatrics and child health. 2019;55:12‐3.
81. Cartwright RD, Crowther CA, Anderson PJ, Harding JE, Doyle LW, McKinlay CJD. Association of Fetal Growth Restriction With Neurocognitive Function After Repeated Antenatal Betamethasone Treatment vs Placebo: Secondary Analysis of the ACTORDS Randomized Clinical Trial. JAMA network open. 2019;2(2):e187636.
82. group Bs, the G, Schmitz T, Alberti C, Aupiais C, Ursino M, et al. Full versus half dose of antenatal betamethasone to prevent severe neonatal respiratory distress syndrome associated with preterm birth: study protocol for a randomised, multicenter, double blind, placebo-controlled, non-inferiority trial (BETADOSE). BMC Pregnancy & Childbirth. 2019;19(1):67-.
83. Vogel JP, Oladapo OT, Pileggi-Castro C, Adejuyigbe EA, Althabe F, Ariff S, et al. Antenatal corticosteroids for women at risk of imminent preterm birth in low-resource countries: the case for equipoise and the need for efficacy trials. BMJ Glob Health. 2017;2(3):e000398.
84. Althabe F, Belizan JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet. 2015 Feb 14;385(9968):629-39.
85. Lee VR, Kaimal AJ, Caughey AB. Cost-effectiveness of antenatal late preterm steroids. American Journal of Obstetrics and Gynecology. 2017;216(1):S233.
86. National Institute for Health and Care Excellence. NICE guideline 25: preterm labour and birth. August, 2019. 2019 [cited December 6, 2019]; Available from:https://www.nice.org.uk/guidance/ng25
87. Committee on Obstetric P. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017 Aug;130(2):e102-e9.
88. Mukerji A, Shah V, Shah PS. Periventricular/Intraventricular Hemorrhage and Neurodevelopmental Outcomes: A Meta-analysis. Pediatrics. 2015 Dec;136(6):1132-43.
89. Gotardo JW, Volkmer NFV, Stangler GP, Dornelles AD, Bohrer BBA, Carvalho CG. Impact of peri-intraventricular haemorrhage and periventricular leukomalacia in the neurodevelopment of preterms: A systematic review and meta-analysis. PLoS One. 2019;14(10):e0223427.
90. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008 Jan 19;371(9608):261-9.
91. Zhang H, Liu J, Liu T, Wang Y, Dai W. Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: A network meta-analysis. Clinical Respiratory Journal. 2018;12(10):2480-90.
92. Gonzalez Garay AG, Reveiz L, Velasco Hidalgo L, Solis Galicia C. Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2014 Oct 31(10):CD009708.
93. Vogel JP, Souza JP, Gulmezoglu AM, Mori R, Lumbiganon P, Qureshi Z, et al. Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. Lancet. 2014 Nov 22;384(9957):1869-77.
94. UN Commission, Born Too soon Care Antenatal Corticosteroids Working Group. Dexamethasone versus betamethasone as an antenatal corticosteroid (ACS). Aug 20, 2013. 2013 [cited Dec 6, 2019]; Available from:https://www.healthynewbornnetwork.org/hnn-content/uploads/ACS-Beta-vs-Dexa-130820.pdf
95. Gyamfi-Bannerman C, Zupancic JAF, Sandoval G, Grobman WA, Blackwell SC, Tita ATN, et al. Cost-effectiveness of Antenatal Corticosteroid Therapy vs No Therapy in Women at Risk of Late Preterm Delivery: A Secondary Analysis of a Randomized Clinical Trial. JAMA Pediatr. 2019 May 1;173(5):462-8.
96. Rosenbloom JI, Lewkowitz AK, Sondgeroth KE, Hudson JL, Macones GA, Cahill AG, et al. Antenatal corticosteroid administration in late-preterm gestations: a cost-effectiveness analysis. Journal of Maternal-Fetal & Neonatal Medicine. 2018;31(22):1-7.
97. Greensides D, Robb-McCord J, Noriega A, Litch JA. Antenatal Corticosteroids for Women at Risk of Imminent Preterm Birth in 7 sub-Saharan African Countries: A Policy and Implementation Landscape Analysis. Global health, science and practice. 2018;6(4):644-56.